Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Activmed Practices & Research Inc

Neither a doctor nor a teaching hospital

Research payments

$675,457

257 payments

Through program year 2024, Activmed Practices & Research Inc is reported as receiving $675,457 in research payments, across 257 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $11,358 2
2023 Research $39,379 7
2021 Research $44,753 26
2020 Research $286,341 125
2019 Research $293,626 97

Breakdown

Who paid Research payments · program years 2019–2024
  1. Celgene Corporation $137,013 4 payments
  2. Incyte Corporation $104,049 100 payments
  3. Dermira, Inc. $95,701 27 payments
  4. Galderma Research & Development, LLC $64,011 2 payments
  5. Sage Therapeutics, Inc. $51,521 22 payments
  6. Amgen Inc. $41,565 12 payments
  7. ACADIA Pharmaceuticals Inc $39,350 9 payments
  8. Vanda Pharmaceuticals Inc. $34,764 14 payments
  9. Sunovion Pharmaceuticals Inc. $32,464 28 payments
  10. Akebia Therapeutics Inc $28,963 26 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $95,701 27 payments
  2. A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double Blind-Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (CC-10004-PSOR-025) $70,030 2 payments
  3. A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) $66,983 2 payments
  4. A Multi-Center Study to Evaluate Subject Reported Outcomes With Use of Trifarotene 50 MCG/G Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris $64,011 2 payments
  5. PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell carcinoma-a window of opportunity trial $43,847 60 payments
  6. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $37,232 30 payments
  7. Dasotraline Binge Eating Disorder Extension Study $29,430 26 payments
  8. Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $26,967 12 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $25,423 3 payments
  10. Acp-103-059 $24,850 7 payments
What the money was spent on Research payments · program years 2019–2024
  1. Other $14,182 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record